Vast Therapeutics Email Format

Biotechnology ResearchNorth Carolina, United States11-50 Employees

Vast Therapeutics is a biotechnology company based in Durham, North Carolina, focused on preclinical airway immunology to disrupt the cycle of infection and chronic inflammation in respiratory diseases. It develops inhaled nitric oxide–based prodrugs formulated as aerosols to target the lungs and address pathogen-driven inflammation in specific patient populations. By leveraging nitric oxide's role in the natural immune response, these compounds are intended as antibiotic alternatives that are not susceptible to common resistance mechanisms.

The company targets patients with chronic lung infections and inflammation, including infections caused by Pseudomonas aeruginosa and Mycobacterium abscessus. A recent development is the presentation of Phase 1 data for the inhaled candidate ALX1 at the ATS 2026 International Conference, indicating progress in clinical development.

Sign up for free to view info

Company overview Employee directory